XML 25 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Financial Information with Respect to Company's Reportable Segments

Presented below is the financial information with respect to the Company’s reportable segments:

		Three Months Ended September 30,
(in thousands)		2019				2018
Revenue:
Therapeutics		$	4,719			$	2,115
Food			146				426
Total segment revenue			4,865				2,541
Segment operational cash expenditures:
Therapeutics		$	14,290			$	11,727
Food			1,942				857
Total segment operational cash expenditures			16,232				12,584
Allocation of centralized research and development operational    cash expenditures:
Therapeutics		$	4,081			$	2,387
Food			—				597
Total allocation of centralized research and development    operational cash expenditures			4,081				2,984
Segment operating loss:
Therapeutics		$	(13,652	)		$	(11,999	)
Food			(1,796	)			(1,028	)
Total segment operating loss			(15,448	)			(13,027	)
Adjustments to reconcile segment operating loss to consolidated    loss from operations:
Corporate general and administrative cash expenditures		$	(6,581	)		$	(3,719	)
Interest income received			(1,236	)			(691	)
Depreciation and amortization			(1,401	)			(584	)
Share-based compensation			(2,491	)			(292	)
Changes in prepaid expenses, accounts payable and accrued expenses			5,179				7,866
Total consolidated loss from operations		$	(21,978	)		$	(10,447	)

		Nine Months Ended September 30,
(in thousands)		2019				2018
Revenue:
Therapeutics		$	14,357			$	5,009
Food			1,359				934
Total segment revenue			15,716				5,943
Segment operational cash expenditures:
Therapeutics		$	42,072			$	25,903
Food			6,126				2,590
Total segment operational cash expenditures			48,198				28,493
Allocation of centralized research and development operational    cash expenditures:
Therapeutics		$	10,952			$	6,329
Food			—				1,830
Total allocation of centralized research and development    operational cash expenditures			10,952				8,159
Segment operating loss:
Therapeutics		$	(38,667	)		$	(27,223	)
Food			(4,767	)			(3,486	)
Total segment operating loss			(43,434	)			(30,709	)
Adjustments to reconcile segment operating loss to consolidated    loss from operations:
Corporate general and administrative cash expenditures		$	(24,726	)		$	(8,397	)
Interest income received			(3,322	)			(1,213	)
Depreciation and amortization			(3,508	)			(1,555	)
Share-based compensation			(6,319	)			(697	)
Loss on disposal of assets			(22	)			(8	)
Changes in prepaid expenses, accounts payable and accrued expenses			15,988				10,772
Total consolidated loss from operations		$	(65,343	)		$	(31,807	)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration